Targeted suppression of DDR2 prevents TA-MSCs from promoting the growth and metastasis of breast cancer cells, possibly due to the loss of the mesenchymal phenotype and downregulation of genes related to tumorigenesis in TA-MSCs [20]. Here, DDR2 is linked to breast carcinoma.